EssilorLuxottica

Board/Management Information • Dec 1, 2025

EssilorLuxottica creates Scientific Advisory Committee to accelerate the next era of innovation

Paris, France (1 December 2025) – EssilorLuxottica announced the creation of its Scientific Advisory Committee, bringing together some of the world's most sought-after scientists and thought leaders from the converging fields of science, technology and healthcare. This initiative will reinforce the Group's enduring scientific foundation and its mission to empower patients and consumers around the world.

The Scientific Advisory Committee will provide strategic guidance and forward-looking insights, helping to maximize EssilorLuxottica's lead agenda. Acting as a catalyst for transformative thinking, the Advisory Committee will collaborate with a global network of leading scientific institutions and advise on new frontiers in the Group's core areas of research, like ophthalmology and oculomics, physics and optics, audiology, AI and ethics.

The Scientific Advisory Committee unites five world-renowned experts, each recognized for their pioneering contributions and leadership in their respective domains:

• Pr. Alain Aspect, PhD, 2022 Nobel laureate in Physics and 2010 Wolf Prize. Professor at Institut d'Optique Graduate School – Université Paris Saclay and École Polytechnique; Emeritus CNRS Senior Scientist.
• Pr. Alessio Figalli, PhD, 2018 Fields medal laureate. Chaired Professor and Director of the Institute for Mathematics Research at ETH Zürich.
• Pr. Sharon Kujawa, PhD, 2017 Callier prize winner. Professor of Otolaryngology Head and Neck Surgery at Harvard Medical School; Principal Investigator at the Eaton-Peabody Laboratories, Mass Eye and Ear.
• Pr. José-Alain Sahel, MD, 2024 Wolf prize winner. Distinguished Professor and Chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine; Emeritus at Sorbonne Université.
• Pr. Effy Vayena, PhD. Professor of Bioethics at ETH Zürich; Visiting Lecturer at the Center for Bioethics, Harvard Medical School.

"Building on EssilorLuxottica's decades of pioneering research and technological breakthroughs, the creation of our first Scientific Advisory Committee marks a defining step in our innovation journey. Engaging with some of the most brilliant minds in science allows us to broaden our horizons, explore uncharted territories and translate knowledge into meaningful human impact. Their expert insights will guide our initiatives to advance ophthalmology, audiology, AI, neuroscience and beyond – amplifying the reach of our solutions across the life sciences. Together we'll continue to shape the future of our industry, driving transformative progress and reaffirming our commitment to lead with purpose", said Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO, of EssilorLuxottica.

Contacts Giorgio Iannella Marco Catalani

ir@essilorluxottica.com media@essilorluxottica.com

Head of Investor Relations Head of Corporate Communications

About EssilorLuxottica EssilorLuxottica is a global leader in the design, manufacture and distribution of advanced vision care products, eyewear and med-tech solutions. The Group is home to the most innovative lens technologies, including Varilux, Stellest and Transitions, iconic brands such as Ray-Ban, Oakley and Supreme, top-selling smart eyewear products including Ray-Ban Meta, Oakley Meta Vanguard and Nuance Audio, the most desired luxury licensed brands and world-class retailers including Sunglass Hut, LensCrafters, Vision Express and Apollo. With over 200,000 employees across 150 countries, 600 operations facilities, serving 300,000 eye care professionals and operating 18,000 stores, the Group generated consolidated revenue of Euro 26.5 billion in 2024. EssilorLuxottica trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP. www.essilorluxottica.com